Aurinia Pharmaceuticals, Inc. (AUPH)
15.86
+0.20
(+1.28%)
USD |
NASDAQ |
Jun 09, 14:16
Aurinia Pharmaceuticals Enterprise Value : 1.738B for June 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| enGene Therapeutics, Inc. | -132.03M |
| Medicus Pharma Ltd. | 10.77M |
| Kiniksa Pharmaceuticals International Plc | 3.302B |
| Xenon Pharmaceuticals, Inc. | 3.861B |
| Psyence Biomedical Ltd. | 3.700M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 34.36M |
| Revenue (Quarterly) | 77.70M |
| Total Expenses (Quarterly) | 43.35M |
| EPS Diluted (Quarterly) | 0.2496 |
| Gross Profit Margin (Quarterly) | 91.63% |
| Profit Margin (Quarterly) | 44.21% |
| Earnings Yield | 13.64% |
| Operating Earnings Yield | 5.97% |
| Normalized Earnings Yield | 13.65 |